Net Income

Logistics giant faces falling profits from weak ocean freight, but a diversification strategy and a massive new share buyback signal long-term confidence.

With over 99% creditor approval, Advantage Solutions restructures its debt, gaining time but facing higher costs and a skeptical stock market.

Tradewinds Universal aims to consolidate the fragmented $8B adult club scene with Peppermint Hippo, but regulatory hurdles and market risks loom large.

As millions of solar panels near retirement, one Tennessee facility is turning a potential waste crisis into a sustainable manufacturing success story.

Medtronic's diabetes arm hits the road for its IPO, seeking to raise up to $784M in a major test of investor appetite for specialized medtech firms.

A student stock competition turns into real-world opportunity, as a Moomoo and W!se partnership awards thousands to NYC schools and their top students.

As tax fraud spikes, Allstate unveils an industry-first plan to give victims their stolen refund money upfront, tackling a growing financial nightmare.

A new report on 1,800+ patients reveals a model for obesity care that preserves muscle, sustains weight loss, and may solve the GLP-1 cost crisis.

Dr. Frank Smith joins XenoSTART to lead its preclinical unit, aiming to leverage its vast patient-derived model library to speed up oncology drug development.

Fresh off strong 2025 earnings, AtriCure will detail its growth strategy and innovative cardiac portfolio at a major life sciences conference.

After a pivotal trial failure, Alector will present its new strategy at a key health conference, focusing on its innovative brain-delivery platform.

The maker of Wegovy and Ozempic announces a massive price cut. We explore what this means for patients, competitors, and the future of drug pricing.

Facing delisting, Hong Kong-based PTL Limited enacts a massive 1-for-80 share consolidation. But can this financial maneuver fix deeper business issues?

New data on MCO-010 gene therapy identifies ideal patients for Retinitis Pigmentosa, a key step as the one-time injection advances toward FDA approval.

Target Hospitality is rapidly expanding workforce housing for AI data centers, revealing the massive, unseen physical infrastructure powering the tech revolution.

As Ring Energy preps its Q4 results, investors eye debt reduction, cost control, and 2026 strategy amid a challenging Permian market.

With pivotal data imminent for its blockbuster hopeful AXPAXLI, Ocular Therapeutix faces a critical month of investor meetings amid commercial headwinds.

With no approved therapies for Hepatitis E, Atea Pharmaceuticals' new drug shows potent preclinical results, offering a potential lifeline for vulnerable patients.

Cell and gene therapy manufacturer OXB posts a dramatic turnaround to profitability, with surging revenues and an ambitious forecast for the coming years.

As Autolus heads to key investor conferences, its strong AUCATZYL® sales and deep pipeline face scrutiny against mounting losses and a curious PR misstep.